Talk:Focal molography
 | This article has not yet been rated on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||
| ||||||||||||||
Copyvio
editRemoving the copyvio issues does not leave an article which makes sense. Onel5969 TT me 01:51, 27 August 2021 (UTC)
Proposed update — incorporating developments 2021–2026
edit | The user below has a request that an edit be made to Focal molography. That user has an actual or apparent conflict of interest. The requested edits backlog is very high. Please be extremely patient. There are currently 564 requests waiting for review. Please read the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies. |
 | The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE. |
I would like to request that the current article be updated with the revised version available at User:Gatterdam/Focal molography draft. The draft has been reviewed and approved by Christof Fattinger (ETH Zurich / F. Hoffmann-La Roche, principal author of the foundational focal molography publications), who confirmed scientific accuracy on 2026-06-09.
Summary of proposed changes:
- Lead: added a sentence noting commercial availability since 2024.
- History → Commercialization (new subsection): founding of lino Biotech AG as an ETH Zurich spin-off in March 2020, Miltenyi Biotec acquisition of lino Biotech in February 2023, and the launch of the MACS Matchmaker (first commercial focal-molography instrument) in October 2024. Sourced from PR Newswire and BioSpace coverage.
- Realization: added a paragraph on total internal reflection focal molography (TIR-M), a variant using objective-side illumination on inverted-microscope platforms (Blickenstorfer et al. 2021, Sensors and Actuators B).
- Applications: expanded with four new subsections backed by peer-reviewed publications from 2025–2026:
- Measurements in complex biological matrices — comparative study against SPR and BLI in 50% bovine serum (Dirscherl et al. 2025, Biosensors).
- Concentration quantification — protein quantification with 97.8–100.3% recovery in cell culture media / 50% FBS (same study).
- Drug discovery / Targeted protein degradation — β-catenin/TCF4 interaction in cell lysate (Cedro et al. 2025, PLOS ONE); 20-plex multiplexed measurement of DNA–VHL ligand conjugates (Raschke et al. 2026, ChemRxiv preprint).
- Bioprocess monitoring — direct titer measurement in bioreactor harvest and cell culture media.
- Comparison with other label-free methods (new section): neutral comparison of FM with SPR, BLI, and ITC, including relative installed base and track record.
- Limitations: updated to reflect commercial status as of 2024.
- References: six new sources added (two press releases for the commercialization timeline; four peer-reviewed papers / one preprint for the application examples).
Disclosure: I am an employee of Miltenyi Biotec, the parent company of lino Biotech AG, which commercializes focal molography. See my user page for the full COI/paid-contribution disclosure. In accordance with the commitment on that user page, I am refraining from editing the article directly and request independent community review per WP:COI and WP:PAID before any changes go live.
A section-aligned side-by-side comparison of the current live article versus the draft is available on request, or can be reproduced from the draft's edit history.
Thank you for your time. — Gatterdam (talk) 11:43, 9 June 2026 (UTC)